One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In September 2016, the U.S. Food and Drug Administration approved the Medtronic 670G “hybrid” closed-loop system. In Auto Mode, this system automatically controls basal insulin delivery based on continuous glucose monitoring data but requires users to enter carbohydrates and blood glucose for boluses. To track real-world experience with this first commercial closed-loop device, we prospectively followed pediatric and adult patients starting the 670G system. RESEARCH DESIGN AND METHODS: This was a 1-year prospective observational study of patients with type 1 diabetes starting the 670G system between May 2017 and May 2018 in clinic. RESULTS: Of the total of 84 patients who received 670G and consented, 5 never returned for follow-up, with 79 (aged 9–61 years) providing data at 1 week and 3, 6, 9, and/or 12 months after Auto Mode initiation. For the 86% (68 out of 79) with 1-week data, 99% (67 out of 68) successfully started. By 3 months, at least 28% (22 out of 79) had stopped using Auto Mode; at 6 months, 34% (27 out of 79); at 9 months, 35% (28 out of 79); and by 12 months, 33% (26 out of 79). The primary reason for continuing Auto Mode was desire for increased time in range. Reasons for discontinuation included sensor issues in 62% (16 out of 26), problems obtaining supplies in 12% (3 out of 26), hypoglycemia fear in 12% (3 out of 26), multiple daily injection preference in 8% (2 out of 26), and sports in 8% (2 out of 26). At all visits, there was a significant correlation between hemoglobin A1c (HbA1c) and Auto Mode utilization. CONCLUSIONS: While Auto Mode utilization correlates with improved glycemic control, a focus on usability and human factors is necessary to ensure use of Auto Mode. Alarms and sensor calibration are a major patient concern, which future technology should alleviate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [210]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384 · cited 7×
“The REDCap platform services are made possible by the Stanford University School of Medicine Research Office.”
MethodInfluential(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 2×
“Middle Eastern 3 (4) 0 (0) 3 (6) Native American 1 (1) 1 (4) 0 (0)”
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 3×
“Prior insulin delivery systems Animas 13 (9) 3 (8) 10 (10) Medtronic, older 62 (45) 19 (49) 43 (44) Medtronic 630G 37 (27) 13 (33) 24 (24) Omnipod 5 (4) 1 (3) 4 (4) Roche 1 (1) 0 (0) 1 (1) Tandem 4 (3) 0 (0) 4 (4) Multiple daily injections 4 (3) 1 (3) 3 (3) Other 11 (8) 2 (5) 9 (9)”
Self-citationTauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
Self-citationSafety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 Diabetes
Forlenza, G. P., Pinhas-Hamiel, O., Liljenquist, D. R., Shulman, D. I., Bailey, T. S., Bode, B. W., Wood, M. A., Buckingham, B. A., Kaiserman, K. B., Shin, J., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0264 · Cited by 182
Self-citation7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Abraham, M. B., Nicholas, J. A., Smith, G. J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., Davis, E. A., Jones, T. W., & on behalf of the PLGM Study Group (2018) · Diabetes Care · doi:10.2337/dc17-1604 · Cited by 142
Cited by
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Self-citationPhillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citation7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Self-citationBergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Self-citation7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
New closed-loop insulin systems
Boughton, C. K., & Hovorka, R. (2021) · Diabetologia · doi:10.1007/s00125-021-05391-w · Cited by 270
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Collyns, O. J., Meier, R. A., Betts, Z. L., Chan, D. S. H., Frampton, C., Frewen, C. M., Hewapathirana, N. M., Jones, S. D., Roy, A., Grosman, B., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2250 · Cited by 276
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0319 · Cited by 230
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
Messer, L. H., Berget, C., Vigers, T., Pyle, L., Geno, C., Wadwa, R. P., Driscoll, K. A., & Forlenza, G. P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12971 · Cited by 161
McAuley, S. A., Lee, M. H., Paldus, B., Vogrin, S., de Bock, M. I., Abraham, M. B., Bach, L. A., Burt, M. G., Cohen, N. D., Colman, P. G., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1447 · Cited by 158
Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions
Templer, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.919942 · Cited by 182
“reasons reported for discontinuation included sensor issues, problems obtaining supplies, and fear of hypoglycemia (32).”
BackgroundISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Hybrid closed‐loop therapy: Where are we in 2021?
Leelarathna, L., Choudhary, P., Wilmot, E. G., Lumb, A., Street, T., Kar, P., & Ng, S. M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14273 · Cited by 141
Berget, C., Messer, L. H., Vigers, T., Frohnert, B. I., Pyle, L., Wadwa, R. P., Driscoll, K. A., & Forlenza, G. P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12962 · Cited by 138
Braune, K., Lal, R. A., Petruželková, L., Scheiner, G., Winterdijk, P., Schmidt, S., Raimond, L., Hood, K. K., Riddell, M. C., Skinner, T. C., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00267-9 · Cited by 130
Self-citationAbraham, M. B., de Bock, M., Smith, G. J., Dart, J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., McAuley, S. A., Keech, A. C., et al. (2021) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2021.3965 · Cited by 121
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
Biester, T., Berget, C., Boughton, C. K., Cudizio, L., Ekhlaspour, L., Hilliard, M. E., Reddy, L., Sap, S. N. U., Schoelwer, M. J., Sherr, J. L., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543034 · Cited by 124
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Moon, S. J., Jung, I., & Park, C.-Y. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0177 · Cited by 98
Ware, J., Boughton, C. K., Allen, J. M., Wilinska, M. E., Tauschmann, M., Denvir, L., Thankamony, A., Campbell, F. M., Wadwa, R. P., Buckingham, B. A., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00020-6 · Cited by 101
Self-citationBoughton, C. K., Hartnell, S., Thabit, H., Poettler, T., Herzig, D., Wilinska, M. E., Ashcroft, N. L., Sibayan, J., Cohen, N., Calhoun, P. M., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14355 · Cited by 100
Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy
Fuchs, J., & Hovorka, R. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1784724 · Cited by 104
Beato-Víbora, P. I., Gallego-Gamero, F., Ambrojo-López, A., Gil-Poch, E., Martín-Romo, I., & Arroyo-Díez, F. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0037 · Cited by 87
Aktürk, H. K., GIORDANO, D. A., Champakanath, A., BRACKETT, S. J., Garg, S. K., & Snell‐Bergeon, J. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13933 · Cited by 82
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Forlenza, G. P., Buckingham, B. A., Brown, S. A., Bode, B. W., Levy, C. J., Criego, A. B., Wadwa, R. P., Cobry, E. C., Slover, R. J., Messer, L. H., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0546 · Cited by 78
Self-citationReal-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes
Messer, L. H., Berget, C., Pyle, L., Vigers, T., Cobry, E., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0165 · Cited by 76
Beato-Víbora, P. I., Gallego-Gamero, F., Lázaro-Martín, L., Romero-Pérez, M. D. M., & Arroyo-Díez, F. J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0400 · Cited by 66
Kudva, Y. C., Laffel, L. M., Brown, S. A., Raghinaru, D., Pinsker, J. E., Ekhlaspour, L., Levy, C. J., Messer, L. H., Kovatchev, B. P., Lum, J. W., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0089 · Cited by 72
Self-citationUnannounced Meal Challenges Using an Advanced Hybrid Closed-Loop System
Shalit, R., Minsky, N., Laron-Hirsh, M., Cohen, O., Kurtz, N., Roy, A., Grosman, B., Benedetti, A., & Tirosh, A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0139 · Cited by 57
Current Status and Emerging Options for Automated Insulin Delivery Systems
Forlenza, G. P., & Lal, R. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0514 · Cited by 78
Self-citationBoscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 80
“1 3 and only 32% of subjects have used auto mode for at least 70% of the time [114].”
BackgroundMethodWheeler, B. J., Collyns, O. J., Meier, R. A., Betts, Z. L., Frampton, C., Frewen, C. M., Galland, B. C., Hewapathirana, N. M., Jones, S., Chan, D. S., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01789-5 · Cited by 70
Reddy, N., Verma, N., & Dungan, K. M. (2020) · MDText.com, Inc. eBooks · Cited by 108
Amadou, C., Franc, S., Benhamou, P.-Y., Lablanche, S., Huneker, E., Charpentier, G., & Penfornis, A. (2021) · Diabetes Care · doi:10.2337/dc20-1809 · Cited by 59
Pease, A., Lo, C., Earnest, A., Kiriakova, V., Liew, D., & Zoungas, S. (2020) · Diabetes Care · doi:10.2337/dc19-1785 · Cited by 70
“people may discontinue hybrid closedloop therapy over 1 year of follow-up due to human factors and practical concerns including alarms and sensor calibration (35).”
BackgroundCobry, E. C., Hamburger, E., & Jaser, S. S. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0057 · Cited by 64
Knoll, C., Peacock, S., Wäldchen, M., Cooper, D., Aulakh, S. K., Raile, K., Hussain, S., & Braune, K. (2022) · Diabetic Medicine · doi:10.1111/dme.14741 · Cited by 58
Petrovski, G., Al Khalaf, F., Campbell, J., Umer, F., Almajaly, D., Hamdan, M., & Hussain, K. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01607-4 · Cited by 56
Amiel, S. A., Potts, L., Goldsmith, K., Jacob, P., Smith, E. L., Gonder-Frederick, L., Heller, S., Toschi, E., Brooks, A., Kariyawasam, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29488-x · Cited by 61
Boughton, C. K., Hartnell, S., Lakshman, R., Nwokolo, M., Wilinska, M. E., Ware, J., Allen, J. M., Evans, M. L., & Hovorka, R. (2023) · Diabetes Care · doi:10.2337/dc23-0728 · Cited by 60
Roos, T., Hermanns, N., Groß, C., Kulzer, B., Haak, T., & Ehrmann, D. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102852 · Cited by 62
The role of automated insulin delivery technology in diabetes
Boughton, C. K., & Hovorka, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06165-w · Cited by 57
“Usability, reflected by a sustained high time spent in closed-loop mode (>95%), is critical to realising the clinical benefits of closed-loop systems [53].”
BackgroundEmerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 66
Fuchs, J., & Hovorka, R. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.679484 · Cited by 61
Barriers to Uptake of Insulin Technologies and Novel Solutions
PAULEY, M. E., Berget, C., Messer, L. H., & Forlenza, G. P. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s312858 · Cited by 73
Longo, M., Caruso, P., Petrizzo, M., Castaldo, F., Sarnataro, A., Gicchino, M., Bellastella, G., Esposito, K., & Maiorino, M. I. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108440 · Cited by 55
“[10] Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM.”
Automated insulin delivery systems: from early research to routine care of type 1 diabetes
Renard, É. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01929-5 · Cited by 58
Kovatchev, B. P., Singh, H., Mueller, L., & Gonder-Frederick, L. A. (2022) · Diabetes Care · doi:10.2337/dc22-1217 · Cited by 49
Diabetes education in pediatrics: How to survive diabetes
Ergun-Longmire, B., Clemente, E. G., Maravolo, P. V., Roberts, C., Buth, K., & Greydanus, D. E. (2021) · Disease-a-Month · doi:10.1016/j.disamonth.2021.101153 · Cited by 54
Berget, C., Aktürk, H. K., Messer, L. H., Vigers, T., Pyle, L. L., Snell‐Bergeon, J. K., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14441 · Cited by 49
Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes
Tanenbaum, M. L., & COMMISSARIAT, P. V. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01469-w · Cited by 50
“, about meals or activity) into the system [52], or if they worry that it will not help prevent lows [33], they may be less likely to adopt or continue to use it.”
BackgroundTraining and Support for Hybrid Closed-Loop Therapy
Boughton, C. K., Hartnell, S., Allen, J. M., Fuchs, J., & Hovorka, R. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820955168 · Cited by 48
Closed-loop insulin delivery: update on the state of the field and emerging technologies
Ware, J., & Hovorka, R. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2142556 · Cited by 47
“adults and another over 6 months in children and young adults (age 2–25 years) [71,72], showed a significant correlation between higher Auto Mode use and lower HbA1c.”
BackgroundNew and Emerging Technologies in Type 1 Diabetes
Sherwood, J. S., Russell, S. J., & Putman, M. S. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.07.006 · Cited by 49
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 83
Cobry, E. C., Berget, C., Messer, L. H., & Forlenza, G. P. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0055 · Cited by 44
Tornese, G., Buzzurro, F., Carletti, C. V., Faleschini, E., & Barbi, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.766314 · Cited by 48
The changing landscape of automated insulin delivery in the management of type 1 diabetes
Lakshman, R., Boughton, C. K., & Hovorka, R. (2023) · Endocrine Connections · doi:10.1530/ec-23-0132 · Cited by 47
Franceschi, R., Mozzillo, E., Candia, F. D., Maines, E., Leonardi, L., Girardi, M., Fedi, L., Rosanio, F. M., & Marcovecchio, M. L. (2023) · Diabetic Medicine · doi:10.1111/dme.15099 · Cited by 48
Berget, C., Sherr, J. L., DeSalvo, D. J., KINGMAN, R. S., Stone, S. L., Brown, S. A., Nguyen, A., Barrett, L., Ly, T. T., & Forlenza, G. P. (2021) · Clinical Diabetes · doi:10.2337/cd21-0083 · Cited by 42
Passanisi, S., Lombardo, F., Mameli, C., Bombaci, B., Macedoni, M., Zuccotti, G., Dovč, K., Battelino, T., Salzano, G., & Delvecchio, M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01501-6 · Cited by 46
PAULEY, M. E., Tommerdahl, K. L., Snell‐Bergeon, J. K., & Forlenza, G. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01799-x · Cited by 46
MCVEAN, J. J. F., & Miller, J. D. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.1926984 · Cited by 41
Jeyaventhan, R., Gallen, G., Choudhary, P., & Hussain, S. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14439 · Cited by 36
Ng, S. M., Katkat, N., Day, H., Hubbard, R. A., Quinn, M., & Finnigan, L. (2022) · Diabetic Medicine · doi:10.1111/dme.14863 · Cited by 41
Burnside, M. J., Lewis, D. M., Crocket, H. R., Wilson, R., Williman, J. A., Jefferies, C., Paul, R. G., Wheeler, B. J., & de Bock, M. I. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00547-8 · Cited by 41
Arunachalum, S., Velado, K., Vigersky, R. A., & Cordero, T. L. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088608 · Cited by 34
The Psychological Implications of Automated Insulin Delivery Systems in Type 1 Diabetes Care
Nefs, G. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.846162 · Cited by 35
Gómez, A. M., Henao, D. C., Parra, D., Kerguelen, A., Pinilla, M. V., Múñoz, Ó., & Rondón, M. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.12.041 · Cited by 34
Datye, K. A., Tilden, D. R., Parmar, A. M., Goethals, E. R., & Jaser, S. S. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01389-1 · Cited by 34
Ma, R., Shao, R., An, X., Zhang, Q., & Sun, S. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00749e · Cited by 36
Nwokolo, M., Lakshman, R., Hartnell, S., Alwan, H., Ware, J., Allen, J. M., Wilinska, M. E., Evans, M. L., Hovorka, R., & Boughton, C. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0262 · Cited by 34
Soni, A., Wright, N. P., Agwu, J. C., Timmis, A., Drew, J., Kershaw, M., Moudiotis, C., Regan, F. M., Williams, E., Wan, J., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109196 · Cited by 33
Boughton, C. K., & Hovorka, R. (2020) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000786 · Cited by 37
The automated pancreas: A review of technologies and clinical practice
Biester, T., Tauschmann, M., Chobot, A. P., Kordonouri, O., Danne, T., Kapellen, T. M., & Dovč, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14576 · Cited by 34
Kubilay, E., Trawley, S. L., Ward, G. M., Fourlanos, S., Grills, C. A., Lee, M. H., MacIsaac, R. J., O'Neal, D. N., O’Regan, N., Sundararajan, V., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.15020 · Cited by 33
Closed-loop systems: recent advancements and lived experiences
Kadiyala, N., Hovorka, R., & Boughton, C. K. (2024) · Expert Review of Medical Devices · doi:10.1080/17434440.2024.2406901 · Cited by 33
“Highlighting the importance of usability, real-world data from the first-generation Medtronic 670 G hybrid closed-loop system showed discontinuation rates of 33% 12 months after starting the technology in adults ([70]) and 30% at 6 months in children [71].”
BackgroundA Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method
Sugumar, V., Ang, K. P., Al-Shanon, A. F., Sethi, G., Yong, P. V. C., Looi, C. Y., & Wong, W. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071406 · Cited by 37
“Closed-loop insulin delivery system 670 G Type 1 diabetes (children, adult) To track the initiation of the FDA-approved 670G closed-loop insulin delivery system NCT03017482 [161]”
BackgroundFeasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses
Nimri, R., Grosman, B., Roy, A., Nir, J., Fisch-Shvalb, N., Kurtz, N., Loewenthal, N., Gillon‐Keren, M., Muller, I., Atlas, E., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0448 · Cited by 31
Varimo, T. J., Pulkkinen, M., Hakonen, E. T., Hero, M. T., Miettinen, P. J., & Tuomaala, A. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13235 · Cited by 29
Mewes, D., Wäldchen, M., Knoll, C., Raile, K., & Braune, K. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221080199 · Cited by 31
Recent advances in closed-loop insulin delivery
Ware, J., & Hovorka, R. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154953 · Cited by 31
Rankin, D., Kimbell, B., Allen, J. M., Besser, R. E. J., Boughton, C. K., Campbell, F., Elleri, D., Fuchs, J., Ghatak, A., Randell, T. L., et al. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821994201 · Cited by 27
Automated Insulin Delivery Systems as a Treatment for Type 2 Diabetes Mellitus: A Review
Karol, A. B., O’Malley, G., Fallurin, R., & Levy, C. J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.001 · Cited by 31
Anandhakrishnan, A., & Hussain, S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15920 · Cited by 28
“61,62 Real-world outcomes with the first commercial closed-loop system, the Medtronic 670G, 63 reported that 62% of those discontinuing after 1 year cited sensor issues, including unplanned system exits from auto mode, as reasons for closed-loop discontinuation.”
Real-World Efficacy of the Hybrid Closed-Loop System
Usoh, C. O., Johnson, C. P., Speiser, J. L., Bundy, R. A., Dharod, A., & Aloi, J. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820985103 · Cited by 23
Lepore, G., Borella, N. D., Castagna, G., Ippolito, S., Bonfadini, S., Corsi, A. M., Scaranna, C., Dodesini, A. R., Bellante, R., & Trevisan, R. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0261 · Cited by 23
O’Malley, G., Messer, L. H., Levy, C. J., Pinsker, J. E., Forlenza, G. P., ISGANAITIS, E. M., Kudva, Y. C., Ekhlaspour, L., Raghinaru, D., Lum, J. W., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0472 · Cited by 23
Self-citationThe Evolution of Diabetes Technology – Options Toward Personalized Care
Zahid, M., Dowlatshahi, S., Kansara, A., & Sadhu, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.007 · Cited by 24
Read, M., Henshaw, K., Zaharieva, D. P., Brown, T. C., Varga, A. E., Bray, C., Cox, M., Goody-Rohdin, P.-J., Hider, K., Jelleyman, P., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110830 · Cited by 20
Lablanche, S., Delagenière, J., Jalbert, M., Sonnet, E., Bénichou, M., Arnold, N., Spiteri, A., Berre, J. P. L., Renard, É., Chevalier, N., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0414 · Cited by 20
Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems
Forlenza, G. P., Dai, Z., Niu, F., & Shin, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0459 · Cited by 25
DuBose, S. N., Bauza, C. E., Verdejo, A. S., Beck, R. W., Bergenstal, R. M., Sherr, J. L., for the HYCLO Study Group, Levy, C. J., Levister, C. M., Lam, D. W.-H., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0176 · Cited by 20
Pease, A., Andrikopoulos, S., Abraham, M. B., Craig, M. E., Fenton, B., Overland, J., Price, S., Simmons, D. S., & Ross, G. P. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51118 · Cited by 20
Closed‐loop technology: a practical guide
Hartnell, S., Fuchs, J., Boughton, C. K., & Hovorka, R. (2021) · Practical Diabetes · doi:10.1002/pdi.2350 · Cited by 22
Metadata
- Authors
- Lal, R. A., Basina, M., Maahs, D. M., Hood, K., Buckingham, B., & Wilson, D. M.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Lal, Rayhan A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-23
- Volume
- 42
- Issue
- 12
- Pages
- 2190-2196
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6868462
- OpenAlex
- W2976192468
- Cited by
- 215
- References
- 29
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 25 · 2023: 35 · 2022: 36 · 2021: 62 · 2020: 33 · 2019: 4
- FWCI
- 27.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1-TR-001085, P30-DK-116074, 1K12-DK-122550)
- National Institute for Diabetes and Digestive and Kidney Diseases (T32-DK-007217, 1K12-DK-122550)
- NIH (DP3-DK-104059, DP3-DK-101055, DK-14024)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- hybrid closed-loop system, type 1 diabetes, continuous glucose monitoring, device utilization, hypoglycemia, sensor calibration, glycemic control, HbA1c, usability, human factors, time in range
- MeSH terms
- Adolescent, Adult, Blood Glucose, Child, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Prospective Studies, United States, Blood Glucose Self-Monitoring, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.